Literature DB >> 28138968

Recurrence after resection with curative intent for distal cholangiocarcinoma.

K Komaya1, T Ebata1, K Shirai2, S Ohira3, N Morofuji4, A Akutagawa5, R Yamaguchi6, M Nagino1.   

Abstract

BACKGROUND: Few studies have been conducted on patterns of recurrence after resection for distal cholangiocarcinoma (DCC). The aim of this study was to investigate the incidence and pattern of recurrence after resection of DCC, and to evaluate prognostic factors for time to recurrence and recurrence-free survival (RFS).
METHODS: Patients who underwent pancreatoduodenectomy with curative intent for DCC between 2001 and 2010 at one of 30 hospitals in Japan were reviewed retrospectively, with special attention to recurrence patterns. The Cox proportional hazards model was used for multivariable analysis.
RESULTS: In the study interval, 389 patients underwent pancreatoduodenectomy for DCC with R0/M0 status. Recurrence developed in 213 patients (54·8 per cent). The estimated cumulative probability of recurrence was 54·3 per cent at 5 years. An initial locoregional recurrence occurred in 55 patients (14·1 per cent) and initial distant recurrence in 168 (43·2 per cent), most commonly in the liver. Isolated initial locoregional recurrence occurred in 45 patients (11·6 per cent). Independent prognostic factors for time to recurrence and RFS were perineural invasion (P = 0·001 and P = 0·009 respectively), pancreatic invasion (both P < 0·001) and lymph node metastasis (both P < 0·001). RFS worsened as the number of risk factors increased: the 5-year RFS rate was 70·6 per cent for patients without any risk factors, 50·3 per cent for patients with one factor, 31·8 per cent for those with two factors, and 13·4 per cent when three factors were present.
CONCLUSION: More than half of patients with DCC experienced recurrence after R0 resection, usually within 5 years. Perineural invasion, pancreatic invasion and positive nodal involvement are risk factors for recurrence.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28138968     DOI: 10.1002/bjs.10452

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  25 in total

1.  Time to Recurrence After Surgical Resection and Survival After Recurrence Among Patients with Perihilar and Distal Cholangiocarcinomas.

Authors:  Yoshitsugu Nakanishi; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Aya Matsui; Kimitaka Tanaka; Soichi Murakami; Yuma Ebihara; Yo Kurashima; Hajime Narasaki; Toraji Amano; Toshiaki Shichinohe; Satoshi Hirano
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

2.  The ABO Blood Group Impacts the Survival of Patients Undergoing Pancreatoduodenectomy for Biliary Tract Cancer.

Authors:  Shozo Mori; Taku Aoki; Kazuma Tago; Takayuki Shimizu; Nobuhiro Harada; Kyung-Hwa Park; Yuhki Sakuraoka; Takayuki Shiraki; Yukihiro Iso; Keiichi Kubota
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?

Authors:  Andrew J Sinnamon; Anthony C Wood; Megan A Satyadi; Catherine V Levitt; Olivia Hardy; Mintallah Haider; Richard D Kim; Daniel A Anaya; Jason W Denbo
Journal:  J Gastrointest Oncol       Date:  2022-06

4.  Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma.

Authors:  Ali Belkouz; Stijn Van Roessel; Marin Strijker; Jacob L van Dam; Lois Daamen; Lydia G van der Geest; Alberto Balduzzi; Andrea Benedetti Cacciaguerra; Susan van Dieren; Quintus Molenaar; Bas Groot Koerkamp; Joanne Verheij; Elizabeth Van Eycken; Giuseppe Malleo; Mohammed Abu Hilal; Martijn G H van Oijen; Ivan Borbath; Chris Verslype; Cornelis J A Punt; Marc G Besselink; Heinz-Josef Klümpen
Journal:  Br J Cancer       Date:  2022-01-17       Impact factor: 9.075

5.  Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.

Authors:  Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

Review 6.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

Review 7.  Surgical Approach to Recurrent Cholangiocarcinoma.

Authors:  Hauke Lang
Journal:  Visc Med       Date:  2020-12-21

8.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

9.  Factors influencing patterns of recurrence following pancreaticoduodenectomy for patients with distal bile duct cancer and ampulla of Vater cancer.

Authors:  Do Hyeon Lee; Hyoung Joo Kim; Chan Woo Cho; Sung Su Yun; Dong-Shik Lee
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-05-31

10.  Prognostic value of lymph nodes count on survival of patients with distal cholangiocarcinomas.

Authors:  Hua-Peng Lin; Sheng-Wei Li; Ye Liu; Shi-Ji Zhou
Journal:  World J Gastroenterol       Date:  2018-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.